Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis.
We investigated the effects of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis induced in rabbits. Clindamycin was encapsulated into liposomes, and suspended in two concentrations: 1 mg/0.1 ml and 2 mg/0.1 ml of clindamycin phosphate. Seven eyes received an intravitreal injection (0.1 ml volume) containing 1 mg of liposome-encapsulated clindamycin and seven eyes received 2 mg. Three control rabbits (six eyes) received drug-free liposomes (three eyes) and no treatment (three eyes). All but one eye treated with clindamycin recovered. All control eyes, including those treated with empty liposomes, were lost to infection.
Rao
V S
VS
LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans.
Peyman
G A
GA
Khoobehi
B
B
Vangipuram
S
S
D000818:Animals; D002981:Clindamycin / Q000008:administration & dosage*; D004337:Drug Carriers; D004341:Drug Evaluation; D009877:Endophthalmitis / Q000188:drug therapy* / Q000209:etiology; D005123:Eye / Q000473:pathology; D007267:Injections; D008081:Liposomes; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013997:Time Factors; D014822:Vitreous Body
D004337:Drug Carriers; D008081:Liposomes; D002981:Clindamycin